A clinical case of cardiovascular toxicity in a patient with multiple myeloma after high-dose self-stem cell-assisted chemotherapy

Подсевалов Владимир Святославович; Гиматдинова Гелия Рифкатовна; Давыдкин Игорь Леонидович; Данилова Олеся Евгеньевна; Хайретдинов Раис Кэтдусович

doi:10.18499/1990-472X-2026-27-2-57-67

A clinical case of cardiovascular toxicity in a patient with multiple myeloma after high-dose self-stem cell-assisted chemotherapy

Authors: ¹, ¹, ¹, ¹, ¹
Affiliations:
1. Samara State Medical University, Dep.of Hospital Therapy with courses in Hematology and Transfusiology
Issue: Vol 27, No 2 (2026): Опубликован 29.06.2026
Pages: 57-67
Section: Внутренние болезни
URL: https://new.vestnik-surgery.com/index.php/1990-472X/article/view/11651
DOI: https://doi.org/10.18499/1990-472X-2026-27-2-57-67

Cite item

Full Text

Abstract
About the authors
References
Statistics

Abstract

Contemporary therapy for multiple myeloma is often associated with cardiovascular toxicity, a consequence of the disease's relapsing nature requiring increasingly aggressive, yet toxic, anti-tumor regimens with each subsequent line of treatment. While the advent of novel therapies has significantly improved patient outcomes in recent years, this positive trend does not preclude the occurrence of adverse events. Patients with pre-existing comorbidities and heightened susceptibility to toxic effects are at particular risk. However, clinical evidence demonstrates that this issue extends beyond comorbid patients; even relatively young individuals without significant concurrent pathology can develop various forms of chemotherapy-associated cardiovascular dysfunction. This clinical review presents a detailed analysis of a case involving hemodynamically significant hypotensive-type cardiovascular toxicity in a 52-year-old patient with multiple myeloma, which developed following high-dose chemotherapy supported by autologous stem cell transplantation. The presented case underscores the necessity for heightened clinical vigilance regarding this complication and justifies the importance of rigorous hemodynamic monitoring throughout the treatment course.